Pharmac will create a new Community and Patient Advisory Committee, a move Associate Health Minister David Seymour says is intended to give patients and consumers a stronger voice in medicine funding decisions. The 4 August announcement says the committee will replace both the current Consumer Advisory Committee and the Consumer and Patient Working Group.
The change is a lifestyle issue as much as a health-policy one. Medicine access affects how people live, work, care for family and plan their futures. A funding decision can determine whether a person can manage pain, keep a job, stay out of hospital or afford treatment without pushing household finances past breaking point. Patient voice is not a nice extra in that process; it is a way to test whether policy understands lived reality.
Seymour said patients used to picket outside Pharmac and now have a stronger voice at the table. The announcement says day-to-day engagement on Pharmac's work will be led by a new Consumer Relations team, working directly with consumer and patient advocates on specific issues. Pharmac will begin recruiting members for the new committee in October, with establishment expected in the new year.
The interim committee will advise on the development and establishment of the new CPAC, including terms of reference, engagement approach and implementation arrangements. Named interim members include Georgina Johnson and Dr Malcolm Mulholland as co-chairs, along with LJ Apaipo, Pui-yi Cheng, Tim Edmonds, Chris Higgins and Tracy Tierney.
The Government also used the announcement to point to funding decisions. Seymour said Pharmac had its largest ever budget of $6.294 billion over four years, including a $604 million uplift, and that since 1 December 2023 it had funded 48 new medicines and widened access to a further 88, with around 767,000 New Zealanders benefiting in the first year of funding.
Those numbers matter, but process still matters too. Patients often judge the system not only by whether a medicine is funded, but by whether explanations are clear, decisions are timely and people feel heard before the outcome is final. A committee cannot remove all disappointment, because funding choices will always involve limits. It can, however, make the decision-making process more informed and less remote.
Consumer advocates will likely watch the detail closely. The committee's influence will depend on who is appointed, how early it sees issues, whether its advice is published or summarised, and whether Pharmac's board and staff respond visibly to the concerns raised. A body that is consulted late will not carry the same weight as one involved early enough to shape options.
For families living with chronic illness, rare conditions or expensive treatments, the promise of earlier and more frequent listening will only become meaningful if it changes how information flows. Patients can explain treatment burden, side effects, access barriers and practical trade-offs that clinical and economic models may not fully capture.
Pharmac's new committee is therefore a useful step, but not a final answer. The public should judge it by whether future medicine decisions become easier to understand, more transparent about trade-offs and more grounded in the everyday lives of people who rely on the system.
